Advancements in Pancreatic Cancer: The Role of Targeted Therapies in Current Research
During a recent X (Twitter) takeover of the OncLive® account for Pancreatic Cancer Awareness Month, Dr. Suneel Kamath discussed the need for more targeted therapies, specifically RAS inhibitors, in pancreatic cancer treatment.
In an interview with OncLive, Kamath outlined key issues in pancreatic cancer treatment. He mentioned the integration of next-generation sequencing (NGS), ongoing research into RAS inhibitors, and other targeted therapies. Kamath is an assistant professor at the Cleveland Clinic Lerner College of Medicine, Case Western Reserve University.
Kamath noted an increase in young-onset pancreatic cancer, particularly in patients aged 15 to 34. He emphasized the importance of being aware that cancer can affect younger individuals. Early detection can significantly improve outcomes.
He highlighted RMC-9805, a promising RAS inhibitor currently in phase 1 trials. This drug targets the active form of the RAS mutation, specifically the KRAS G12D variant found in about 40% of pancreatic cancer patients. Early trial data showed a 30% overall response rate and an 80% disease control rate, indicating favorable results for such a challenging patient population. Kamath expects better outcomes if RMC-9805 is used earlier in treatment.
What recent advancements have been made in pancreatic cancer treatment strategies?
Interview with Dr. Suneel Kamath: Advancements in Pancreatic Cancer Treatment and teh Promise of RAS Inhibitors
In a recent takeover of the OncLive® account for Pancreatic Cancer Awareness Month, Dr. Suneel Kamath shed light on the critical need for advancements in pancreatic cancer treatment. As an assistant professor at the Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Kamath advocates for more targeted therapies, especially focusing on RAS inhibitors.
OncLive: Dr. Kamath, you mentioned the increasing prevalence of pancreatic cancer among younger individuals. Can you elaborate on this trend?
Dr. Kamath: Absolutely. There has been a noticeable increase in young-onset pancreatic cancer, notably among patients aged 15 to 34. It’s vital for both the medical community and the public to recognize that pancreatic cancer is not just an older adult disease. Raising awareness can lead to earlier detection, which is crucial because it can significantly improve outcomes for these patients.
OncLive: you touched upon the integration of next-generation sequencing (NGS) in treatment. How is NGS impacting the approach to pancreatic cancer?
Dr.Kamath: NGS testing is transformative for treating pancreatic cancer. While actionable mutations are rare,when they are identified,targeted therapies can be incredibly effective. In our practice, we emphasize thorough testing, utilizing both tissue samples and liquid biopsies to pinpoint potential targets for therapy. I’ve also found that using fine-needle biopsies instead of customary FNAs has greatly enhanced our testing outcomes at the Cleveland Clinic.
OncLive: Let’s discuss RAS inhibitors, particularly RMC-9805. What makes this drug a promising advancement in pancreatic cancer treatment?
Dr. Kamath: RMC-9805 is a RAS inhibitor currently in phase 1 trials, specifically targeting the KRAS G12D variant that is present in about 40% of pancreatic cancer cases. Early data is encouraging, showing a 30% overall response rate and an 80% disease control rate. What’s exciting is that if we use RMC-9805 earlier in the treatment process, I anticipate even better outcomes for these patients.
OncLive: In your opinion, what should be the next steps for physicians treating pancreatic cancer?
Dr. Kamath: Physicians must prioritize thorough and comprehensive genetic testing. This means not only looking for mutations but also investigating the best strategies for treatment, including the potential integration of drugs like RMC-9805. I stress the importance of using fine-needle biopsies, as it helps to secure more viable tissue for testing, ultimately allowing us to offer precision therapies that are specifically tailored for each patient.
OncLive: What does the future hold for RMC-9805 and RAS inhibitors in pancreatic cancer?
Dr.Kamath: The ongoing research by Revolution Medicines on RMC-9805 could position it as a crucial player in the fight against pancreatic cancer.The data we’ve seen so far is promising, and as we continue to learn more about this drug and its efficacy, it could become a vital part of our treatment arsenal in the near future.
This conversation underscores the urgent need for innovation and a tailored approach in treating pancreatic cancer, particularly as we face rising incidence rates among younger patients.
Kamath also discussed the role of NGS testing for pancreatic cancer. While actionable mutations are rare, targeted therapies can be very effective. Some treatments have tissue-agnostic approvals for various mutations. Kamath stressed the need for thorough testing, including both tissue samples and liquid biopsies, to identify potential targets for therapy.
He recommended that physicians conduct fine-needle biopsies over traditional FNAs to ensure sufficient tissue for NGS testing. This practice has improved testing outcomes at Cleveland Clinic.
Revolution Medicines is conducting further research on RMC-9805, which may become a vital part of pancreatic cancer treatment in the future.